Tumor News and Research

RSS

Prognostic factors could aid RCC metastasectomy decisions

Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma.

22 Oct 2013

Stage and grade dominate RCC outcomes

Tumor grade and American Joint Committee on Cancer stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma.

22 Oct 2013

REGARD VEGF receptor-2 as gastric cancer target

Targeting vascular endothelial growth factor receptor-2 mediated signaling is an effective strategy against advanced gastric cancer, results from the REGARD trial demonstrate.

22 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

Risk for breast cancer: Key prevention awareness tips for young women

Breast cancer prevention needs to become a shared conversation among women of all ages as it can strike at any age, and is generally more aggressive when diagnosed in women under the age of 50. With hopes to spark that discussion, Isabelle Mercier, PhD, a research assistant professor at University of the Sciences, compiled some key prevention awareness tips for young women.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

Study: Elevated BMI may affect survival in pancreatic cancer patients

New results from a prospective study published in the Journal of Clinical Oncology show that patients with a body mass index (BMI) in the obese range live on average two to three months less after a pancreatic cancer diagnosis, compared with healthy weight patients, even after adjusting for factors that are known to predict survival for patients with this disease, such as age and disease stage.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Skin cancer drug shows periocular promise

Early research suggests that patients with periocular basal cell carcinoma may benefit from treatment with a drug targeting the Hedgehog signaling pathway.

21 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

UCLA study uncovers biological clock that may shed light on why our bodies age

Everyone grows older, but scientists don't really understand why. Now a UCLA study has uncovered a biological clock embedded in our genomes that may shed light on why our bodies age and how we can slow the process.

21 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

Certain food and lifestyle habits can turn on or off expression of cancer related genes

Research performed at the Center of Research and Advanced Studies (Cinvestav) has identified that certain food and lifestyle habits can turn on or off the expression of cancer related genes.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

New research identifies internal timepiece that accurately gauge age of human organs and tissues

21 Oct 2013

Tumor News and Research

Prognostic factors could aid RCC metastasectomy decisions

Stage and grade dominate RCC outcomes

REGARD VEGF receptor-2 as gastric cancer target

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Risk for breast cancer: Key prevention awareness tips for young women

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Study: Elevated BMI may affect survival in pancreatic cancer patients

Pancreatic cancer patients may benefit from antibody-drug conjugates

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Skin cancer drug shows periocular promise

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

UCLA study uncovers biological clock that may shed light on why our bodies age

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

New investigational drug offers potential treatment option for lung cancer

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Certain food and lifestyle habits can turn on or off expression of cancer related genes

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

New research identifies internal timepiece that accurately gauge age of human organs and tissues

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News